. 2021 Sep;20(9):739-752.

doi: 10.1016/S1474-4422(21)00214-3.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Elisabeth H Thijssen¹, Renaud La Joie², Amelia Strom², Corrina Fonseca², Leonardo Iaccarino², Amy Wolf², Salvatore Spina², Isabel E Allen³, Yann Cobigo², Hilary Heuer², Lawren VandeVrede², Nicholas K Proctor⁴, Argentina Lario Lago², Suzanne Baker⁵, Rajeev Sivasankaran⁶, Agnieszka Kieloch⁶, Arvind Kinhikar⁶, Lili Yu⁶, Marie-Anne Valentin⁶, Andreas Jeromin⁷, Henrik Zetterberg⁸, Oskar Hansson⁹, Niklas Mattsson-Carlgren¹⁰, Danielle Graham¹¹, Kaj Blennow¹², Joel H Kramer², Lea T Grinberg¹³, William W Seeley¹³, Howard Rosen², Bradley F Boeve¹⁴, Bruce L Miller², Charlotte E Teunissen¹⁵, Gil D Rabinovici¹⁶, Julio C Rojas², Jeffrey L Dage⁴, Adam L Boxer¹⁷; Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators

Affiliations

¹ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands.
² Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
³ Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
⁶ Novartis, Cambridge, MA, USA.
⁷ Quanterix, Billerica, MA, USA.
⁸ Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at UCL, University College London, London, UK.
⁹ Clinical Memory Research Unit, Lund University, Lund, Sweden.
¹⁰ Clinical Memory Research Unit, Lund University, Lund, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.
¹¹ Biogen, Cambridge, MA, USA.
¹² Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
¹³ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, CA, USA.
¹⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁵ Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands.
¹⁶ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Department of Radiology & Biomedical Imaging, University of California, San Francisco, CA, USA.
¹⁷ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. Electronic address: adam.boxer@ucsf.edu.

PMID: 34418401
PMCID: PMC8711249
DOI: 10.1016/S1474-4422(21)00214-3

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Elisabeth H Thijssen et al. Lancet Neurol. 2021 Sep.

. 2021 Sep;20(9):739-752.

doi: 10.1016/S1474-4422(21)00214-3.

Authors

Affiliations

¹ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands.
² Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
³ Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
⁶ Novartis, Cambridge, MA, USA.
⁷ Quanterix, Billerica, MA, USA.
⁸ Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at UCL, University College London, London, UK.
⁹ Clinical Memory Research Unit, Lund University, Lund, Sweden.
¹⁰ Clinical Memory Research Unit, Lund University, Lund, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.
¹¹ Biogen, Cambridge, MA, USA.
¹² Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
¹³ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, CA, USA.
¹⁴ Department of Neurology, Mayo Clinic, Rochester, MN, USA.
¹⁵ Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands.
¹⁶ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA; Department of Radiology & Biomedical Imaging, University of California, San Francisco, CA, USA.
¹⁷ Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. Electronic address: adam.boxer@ucsf.edu.

PMID: 34418401
PMCID: PMC8711249
DOI: 10.1016/S1474-4422(21)00214-3

Erratum in

Correction to Lancet Neurol 2021; 20: 739-52.
[No authors listed] [No authors listed] Lancet Neurol. 2021 Oct;20(10):e6. doi: 10.1016/S1474-4422(21)00286-6. Epub 2021 Aug 31. Lancet Neurol. 2021. PMID: 34478638 No abstract available.

Abstract

Background: Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau pathology. We compared the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer's disease syndromes, or frontotemporal lobar degeneration (FTLD) syndromes.

Methods: In this retrospective multicohort diagnostic performance study, we analysed plasma samples, obtained from patients aged 18-99 years old who had been diagnosed with Alzheimer's disease syndromes (Alzheimer's disease dementia, logopenic variant primary progressive aphasia, or posterior cortical atrophy), FTLD syndromes (corticobasal syndrome, progressive supranuclear palsy, behavioural variant frontotemporal dementia, non-fluent variant primary progressive aphasia, or semantic variant primary progressive aphasia), or mild cognitive impairment; the participants were from the University of California San Francisco (UCSF) Memory and Aging Center, San Francisco, CA, USA, and the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium (ARTFL; 17 sites in the USA and two in Canada). Participants from both cohorts were carefully characterised, including assessments of CSF p-tau181, amyloid-PET or tau-PET (or both), and clinical and cognitive evaluations. Plasma p-tau181 and p-tau217 were measured using electrochemiluminescence-based assays, which differed only in the biotinylated antibody epitope specificity. Receiver operating characteristic analyses were used to determine diagnostic accuracy of both plasma markers using clinical diagnosis, neuropathological findings, and amyloid-PET and tau-PET measures as gold standards. Difference between two area under the curve (AUC) analyses were tested with the Delong test.

Findings: Data were collected from 593 participants (443 from UCSF and 150 from ARTFL, mean age 64 years [SD 13], 294 [50%] women) between July 1 and Nov 30, 2020. Plasma p-tau217 and p-tau181 were correlated (r=0·90, p<0·0001). Both p-tau217 and p-tau181 concentrations were increased in people with Alzheimer's disease syndromes (n=75, mean age 65 years [SD 10]) relative to cognitively unimpaired controls (n=118, mean age 61 years [SD 18]; AUC=0·98 [95% CI 0·95-1·00] for p-tau217, AUC=0·97 [0·94-0·99] for p-tau181; p_diff=0·31) and in pathology-confirmed Alzheimer's disease (n=15, mean age 73 years [SD 12]) versus pathologically confirmed FTLD (n=68, mean age 67 years [SD 8]; AUC=0·96 [0·92-1·00] for p-tau217, AUC=0·91 [0·82-1·00] for p-tau181; p_diff=0·22). P-tau217 outperformed p-tau181 in differentiating patients with Alzheimer's disease syndromes (n=75) from those with FTLD syndromes (n=274, mean age 67 years [SD 9]; AUC=0·93 [0·91-0·96] for p-tau217, AUC=0·91 [0·88-0·94] for p-tau181; p_diff=0·01). P-tau217 was a stronger indicator of amyloid-PET positivity (n=146, AUC=0·91 [0·88-0·94]) than was p-tau181 (n=214, AUC=0·89 [0·86-0·93]; p_diff=0·049). Tau-PET binding in the temporal cortex was more strongly associated with p-tau217 than p-tau181 (r=0·80 vs r=0·72; p_diff<0·0001, n=230).

Interpretation: Both p-tau217 and p-tau181 had excellent diagnostic performance for differentiating patients with Alzheimer's disease syndromes from other neurodegenerative disorders. There was some evidence in favour of p-tau217 compared with p-tau181 for differential diagnosis of Alzheimer's disease syndromes versus FTLD syndromes, as an indication of amyloid-PET-positivity, and for stronger correlations with tau-PET signal. Pending replication in independent, diverse, and older cohorts, plasma p-tau217 and p-tau181 could be useful screening tools to identify individuals with underlying amyloid and Alzheimer's disease tau pathology.

Funding: US National Institutes of Health, State of California Department of Health Services, Rainwater Charitable Foundation, Michael J Fox foundation, Association for Frontotemporal Degeneration, Alzheimer's Association.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JLD and NKP are employees of Eli Lilly and Company, which is exploring commercial development opportunities for p-tau assays. JLD is listed as an inventor on a patent related to reagents used in the p-tau assays. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a cofounder of Brain Biomarker Solutions (BBS) in Gothenburg AB, which is a part of the GU Ventures Incubator Program. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy or speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. KB served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a cofounder of BBS in Gothenburg AB, outside the submitted work. LTG receives research support from Avid Radiopharmaceuticals and Eli Lilly. She has received consulting fees from the Simon Foundation and Cura Sen, and serves as associate editor for Frontiers in Aging Neurosciences, Frontiers in Dementia, and the Journal of Alzheimer Disease. HR has received research support from Biogen Pharmaceuticals, has consulting agreements with Wave Neuroscience and Ionis Pharmaceuticals, and receives research support from US National Institutes of Health (NIH). BFB receives research support from NIH, the Mangurian Foundation, and the Little Family Foundation. He is on the Scientific Advisory Board for the Tau Consortium, and has received grant support for clinical trials from Biogen, Alector, and EIP Pharma. GDR receives research support from NIH, Alzheimer's Association, American College of Radiology, Rainwater Charitable Foundation, Avid Radiopharmaceuticals, Eli Lilly, GE Healthcare, and Life Molecular Imaging. He has served as a consultant for Eisai, Merck, Axon Neurosciences, and Johnson & Johnson, and has received speaking honoraria from GE Healthcare. He serves as Associate Editor for JAMA Neurology. JCR is a site principal investigator for clinical trials supported by Eli Lilly and receives support from NIH. ALB receives research support from the NIH, the Rainwater Charitable Foundation, the Association for Frontotemporal Degeneration, Bluefield Project to Cure Frontotemporal Dementia, the Alzheimer's Drug Discovery Foundation, and the Alzheimer's Association. He has served as a consultant for Alector, AGTC, Arkuda, Arvinas, AZTherapies, GSK, Oligomerix, Ono, Regeneron, Roche, Samumed, Stealth, Third Rock, Transposon, and Wave, and received research support from Biogen, Eisai, and Regeneron. All other authors declare no competing interests.

Figures

**Figure 1.. P-tau217 and P-tau181 concentrations per clinical diagnosis.**
A. P-tau217 was increased in the AD spectrum compared to all other diagnoses. B. P-tau18 was increased in the AD-spectrum compared to all other diagnoses. C. ROC curve analyses of the differentiation between the patients in the AD-spectrum and the normal controls. Brown represents P-tau217, pink represents P-tau181. D. ROC curve analyses of the differentiation between the patients in the AD-spectrum and patients in the FTLD-spectrum. Brown represents P-tau217, pink represents P-tau181. *Significant difference in AUC. For visualization, raw biomarker concentrations were used.

**Figure 2.. P-tau217 and P-tau181 concentrations per pathology confirmed diagnosis and *MAPT* genotype.**
A. P-tau217 was increased in the pathology confirmed AD group compared to the FTLD-TDP and FTLD-tau groups. B. P-tau181 was increased in the pathology confirmed AD group compared to the FTLD-TDP and FTLD-tau groups. C. ROC curve analyses of the differentiation between the pathology-confirmed AD and FTLD-tau combined with the FTLD-TDP participants. Brown represents P-tau217, pink represents P-tau181. D. There was no difference in P-tau217 concentrations between 4R (n=33, 58% female, mean age=41.8), 3R/4R (n=11, 45% female, mean age=45.3) *MAPT* and age and sex matched amyloid-PET-negative controls (n=8, 50% female, mean age=50.7). E. There was no difference in P-tau181 concentrations between 4R, 3R/4R *MAPT* and age and sex matched controls. Three of the five *MAPT* mutation carriers with the highest P-tau values (P-tau217>0.5 pg/mL or P-tau181>2.0 pg/mL) had a known CSF P-tau concentration which was also high (>30 pg/mL).***p<0·0001, adjusted for sex, age, CDRsb (and time between plasma sample and death for pathology-confirmed participants). For visualization, raw biomarker concentrations were used, although natural log transformed data were used for ANCOVA.

**Figure 3.. Association between P-tau217, P-tau181, amyloid-PET and tau-PET.**
A. The correlation between plasma P-tau217 and temporal tau-PET SUVR, shapes show clinical diagnosis and color shows amyloid-PET status. The dotted line is the cut-off value for tau-PET positivity of 1.27 SUVR. Correlation coefficient indicates Pearson’s correlation on raw plasma and PET values, but correlation strength was not impacted by log-transformation of P-tau217 values (r=0.80) or using rank correlation (Spearman ρ=0.79). B. The correlation between plasma P-tau181 and temporal tau-PET SUVR. Correlation strength was little impacted by log-transformation of P-tau181 (r=0.72) or rank correlation (Spearman ρ=0.72). C. Differentiation between amyloid-PET-positive and -negative, by boxplot and ROC AUC. Brown represents P-tau217, pink represents P-tau181. D. Differentiation between tau-PET-positive and -negative, by boxplot and ROC AUC. Brown represents P-tau217, pink represents P-tau181. *Significant difference in AUC, adjusted for sex, age. For visualization, raw biomarker concentrations were used, although natural log transformed data were used for ANCOVA.

**Figure 4.. Voxelwise correlation between plasma P-tau217, P-tau181 and Tau-PET tracer binding or grey matter volume.**
The density plots on top of the color bars show the distribution of Pearson’s r values across all voxels included in the GM cortex mask. The pink lines in the color bar indicate p<0·0001 at the voxel level for tau-PET, green lines in the color bar indicate p<0·0001 for grey matter atrophy, and correspond to various r values depending on each subsample size. The voxelwise correlation brain maps are available on Neurovault: https://neurovault.org/collections/SDXLLPNR/

See this image and copyright information in PMC

Comment in

A blood test for Alzheimer's disease: a step forward.
Parnetti L, Filippo MD, Gaetani L. Parnetti L, et al. Lancet Neurol. 2021 Sep;20(9):691-693. doi: 10.1016/S1474-4422(21)00254-4. Lancet Neurol. 2021. PMID: 34418386 No abstract available.

References

1. Ossenkoppele R et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. Jama 320, doi: 10.1001/jama.2018.12917 (2018). - DOI - PMC - PubMed
1. Dugger BN et al. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurology 15, 146, doi: 10.1186/s12883-015-0403-4 (2015). - DOI - PMC - PubMed
1. Altomare D et al. Applying the ATN scheme in a memory clinic population: The ABIDE project. Neurology 93, e1635–e1646, doi: 10.1212/WNL.0000000000008361 (2019). - DOI - PubMed
1. Pardini M et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 92, e1121–e1135, doi: 10.1212/WNL.0000000000007038 (2019). - DOI - PMC - PubMed
1. Irwin DJ et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. The Lancet Neurology 16, 55–65, doi: 10.1016/s1474-4422(16)30291-5 (2017). - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Affiliations

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

Comment in

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical